These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
330 related articles for article (PubMed ID: 29122306)
1. Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery. Roux A; Caire F; Guyotat J; Menei P; Metellus P; Pallud J; Neurochirurgie; 2017 Dec; 63(6):433-443. PubMed ID: 29122306 [TBL] [Abstract][Full Text] [Related]
2. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840 [TBL] [Abstract][Full Text] [Related]
3. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas. Noël G; Schott R; Froelich S; Gaub MP; Boyer P; Fischer-Lokou D; Dufour P; Kehrli P; Maitrot D Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):749-55. PubMed ID: 21300471 [TBL] [Abstract][Full Text] [Related]
4. Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review. Ashby LS; Smith KA; Stea B World J Surg Oncol; 2016 Aug; 14(1):225. PubMed ID: 27557526 [TBL] [Abstract][Full Text] [Related]
5. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757 [TBL] [Abstract][Full Text] [Related]
6. Extent of resection and Carmustine wafer implantation safely improve survival in patients with a newly diagnosed glioblastoma: a single center experience of the current practice. Roux A; Peeters S; Zanello M; Bou Nassif R; Abi Lahoud G; Dezamis E; Parraga E; Lechapt-Zalcmann E; Dhermain F; Dumont S; Louvel G; Chretien F; Sauvageon X; Devaux B; Oppenheim C; Pallud J J Neurooncol; 2017 Oct; 135(1):83-92. PubMed ID: 28669011 [TBL] [Abstract][Full Text] [Related]
7. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers. Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801 [TBL] [Abstract][Full Text] [Related]
8. Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. Lin SH; Kleinberg LR Expert Rev Anticancer Ther; 2008 Mar; 8(3):343-59. PubMed ID: 18366283 [TBL] [Abstract][Full Text] [Related]
9. Importance and accuracy of intraoperative frozen section diagnosis of the resection margin for effective carmustine wafer implantation. Asano K; Kurose A; Kamataki A; Kato N; Ogawa K; Katayama K; Kakuta K; Fumoto T; Ohkuma H Brain Tumor Pathol; 2018 Jul; 35(3):131-140. PubMed ID: 29948295 [TBL] [Abstract][Full Text] [Related]
10. Patterns of Recurrence After Resection of Malignant Gliomas With BCNU Wafer Implants: Retrospective Review in a Single Institution. Shimato S; Nishizawa T; Ohshima T; Imai T; Goto S; Yamamoto T; Kato K World Neurosurg; 2016 Jun; 90():340-347. PubMed ID: 26960286 [TBL] [Abstract][Full Text] [Related]
11. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide. Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215 [TBL] [Abstract][Full Text] [Related]
12. Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort. Pallud J; Audureau E; Noel G; Corns R; Lechapt-Zalcman E; Duntze J; Pavlov V; Guyotat J; Hieu PD; Le Reste PJ; Faillot T; Litre CF; Desse N; Petit A; Emery E; Voirin J; Peltier J; Caire F; Vignes JR; Barat JL; Langlois O; Dezamis E; Parraga E; Zanello M; Nader E; Lefranc M; Bauchet L; Devaux B; Menei P; Metellus P; Neuro Oncol; 2015 Dec; 17(12):1609-19. PubMed ID: 26185110 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma. Samis Zella MA; Wallocha M; Slotty PJ; Isik G; Hänggi D; Schroeteler J; Ewelt C; Steiger HJ; Sabel M Acta Neurochir (Wien); 2014 Feb; 156(2):313-23. PubMed ID: 24287680 [TBL] [Abstract][Full Text] [Related]
14. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Affronti ML; Heery CR; Herndon JE; Rich JN; Reardon DA; Desjardins A; Vredenburgh JJ; Friedman AH; Bigner DD; Friedman HS Cancer; 2009 Aug; 115(15):3501-11. PubMed ID: 19514083 [TBL] [Abstract][Full Text] [Related]
15. Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience. Akiyama Y; Kimura Y; Enatsu R; Mikami T; Wanibuchi M; Mikuni N World Neurosurg; 2018 May; 113():e508-e514. PubMed ID: 29476996 [TBL] [Abstract][Full Text] [Related]
16. Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases. Duntze J; Litré CF; Eap C; Théret E; Debreuve A; Jovenin N; Lechapt-Zalcman E; Metellus P; Colin P; Guillamo JS; Emery E; Menei P; Rousseaux P; Peruzzi P Ann Surg Oncol; 2013 Jun; 20(6):2065-72. PubMed ID: 23212763 [TBL] [Abstract][Full Text] [Related]
17. Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. Menei P; Metellus P; Parot-Schinkel E; Loiseau H; Capelle L; Jacquet G; Guyotat J; Ann Surg Oncol; 2010 Jul; 17(7):1740-6. PubMed ID: 20443147 [TBL] [Abstract][Full Text] [Related]
18. The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience. Gutenberg A; Lumenta CB; Braunsdorf WE; Sabel M; Mehdorn HM; Westphal M; Giese A J Neurooncol; 2013 Jun; 113(2):163-74. PubMed ID: 23535992 [TBL] [Abstract][Full Text] [Related]
19. BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase II trial. Burri SH; Prabhu RS; Sumrall AL; Brick W; Blaker BD; Heideman BE; Boltes P; Kelly R; Symanowski JT; Wiggins WF; Ashby L; Norton HJ; Judy K; Asher AL J Neurooncol; 2015 Jun; 123(2):259-66. PubMed ID: 25947286 [TBL] [Abstract][Full Text] [Related]
20. Carmustine wafer implantation when surgical cavity is communicating with cerebral ventricles: technical considerations on a clinical series. Della Puppa A; Rossetto M; Ciccarino P; Denaro L; Rotilio A; d'Avella D; Scienza R World Neurosurg; 2011; 76(1-2):156-9; discussion 67-8. PubMed ID: 21839967 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]